Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03848-9
Abstract: PurposeEpidermal growth factor receptor (EGFR) is highly expressed on non-small cell lung cancers (NSCLC) and a valuable therapeutic target. This study aimed at producing and characterizing monomethyl auristatin E (MMAE)-conjugated anti-EGFR antibody as a novel… read more here.
Keywords: rc68 pab; mmae; egfr; pab mmae ... See more keywords
Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0440
Abstract: Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for four FDA-approved antibody drug conjugates (ADCs). Deconjugated MMAE readily diffuses into untargeted cells resulting in off-target toxicity. Here we… read more here.
Keywords: cell; drug conjugates; mmae; administration abc3315 ... See more keywords
Abstract B40: Anti-EMP2 IgG Mono Methyl Auristatin E (MMAE) antibody-drug conjugate (ADC) as a potential cancer therapeutic
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.pmccavuln16-b40
Abstract: Despite significant advances in biology and medicine, the incidence and mortality due to cancer world-wide is still unacceptably high. With the goal of detection and eradication of disease, our overall strategy had been to identify… read more here.
Keywords: mmae; antibody; drug conjugate; anti emp2 ... See more keywords
Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0525-0
Abstract: BackgroundAberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here… read more here.
Keywords: mmae; pancreatic cancer; drug; cancer ... See more keywords
Bivalent EGFR-Targeting DARPin-MMAE Conjugates
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23052468
Abstract: Epidermal growth factor receptor (EGFR) is a validated tumor marker overexpressed in various cancers such as squamous cell carcinoma (SSC) of the head and neck and gliomas. We constructed protein-drug conjugates based on the anti-EGFR… read more here.
Keywords: dd1 mmae; bivalent egfr; mmae conjugates; mmae ... See more keywords
Old Drug, New Delivery Strategy: MMAE Repackaged
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24108543
Abstract: Targeting therapy is a concept that has gained significant importance in recent years, especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate the development of novel, efficient and tolerable therapy approaches. In this… read more here.
Keywords: mmae; psma; drug; old drug ... See more keywords